{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:42:59Z","timestamp":1792082579647,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1128003"],"award-info":[{"award-number":["1128003"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1148700"],"award-info":[{"award-number":["1148700"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1166753"],"award-info":[{"award-number":["1166753"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1104975"],"award-info":[{"award-number":["1104975"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Centre of Research Excellence on Malaria Elimination","award":["1134989"],"award-info":[{"award-number":["1134989"]}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.pt.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:12:46Z","timestamp":1559693566000},"page":"529-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria"],"prefix":"10.1016","volume":"35","author":[{"given":"Carlo","family":"Giannangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya J.I.","family":"Fowkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Charman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-7082","authenticated-orcid":false,"given":"Darren J.","family":"Creek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2019.05.002_bb0005","series-title":"World Malaria Report 2018","author":"WHO","year":"2018"},{"key":"10.1016\/j.pt.2019.05.002_bb0010","series-title":"Guidelines for the Treatment of Malaria","author":"WHO","year":"2015"},{"key":"10.1016\/j.pt.2019.05.002_bb0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2019.05.002_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/femsre\/fuw037","article-title":"The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread","volume":"41","author":"Woodrow","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.pt.2019.05.002_bb0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2019.05.002_bb0030","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1056\/NEJMc1713777","article-title":"Evidence of artemisinin-resistant Plasmodium falciparum malaria in eastern India","volume":"379","author":"Das","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2019.05.002_bb0035","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.pt.2016.05.010","article-title":"Artemisinin action and resistance in Plasmodium falciparum","volume":"32","author":"Tilley","year":"2016","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2019.05.002_bb0040","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1073\/pnas.1600459113","article-title":"Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7","volume":"113","author":"Ismail","year":"2016","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2019.05.002_bb0045","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1038\/ncomms10111","article-title":"Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2019.05.002_bb0050","doi-asserted-by":"crossref","first-page":"13676","DOI":"10.1073\/pnas.0500972102","article-title":"The antimalarial drug artemisinin alkylates heme in infected mice","volume":"102","author":"Robert","year":"2005","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2019.05.002_bb0055","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-018-06221-1","article-title":"Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome","volume":"9","author":"Bridgford","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2019.05.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002132","article-title":"Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance","volume":"13","author":"Dogovski","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.pt.2019.05.002_bb0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1475-2875-10-263","article-title":"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration","volume":"10","author":"Morris","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0070","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nature02779","article-title":"Identification of an antimalarial synthetic trioxolane drug development candidate","volume":"430","author":"Vennerstrom","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pt.2019.05.002_bb0075","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1021\/jm049040u","article-title":"Spiro and dispiro-1, 2, 4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes","volume":"48","author":"Dong","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2019.05.002_bb0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/cid\/cis475","article-title":"Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial","volume":"55","author":"Valecha","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1086\/655831","article-title":"Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial","volume":"51","author":"Valecha","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12936-015-0982-y","article-title":"Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study","volume":"14","author":"Toure","year":"2015","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jcph.232","article-title":"Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects","volume":"54","author":"Saha","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2019.05.002_bb0100","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2019.05.002_bb0105","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1021\/acs.jmedchem.6b01586","article-title":"Structure\u2013activity relationship of the antimalarial ozonide artefenomel (OZ439)","volume":"60","author":"Dong","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2019.05.002_bb0110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2125.2012.04368.x","article-title":"First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials","volume":"75","author":"Moehrle","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2019.05.002_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12916-017-0940-3","article-title":"A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria","volume":"15","author":"Macintyre","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.pt.2019.05.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01068-18","article-title":"Investigating the efficacy of triple artemisinin-based combination therapies for treating Plasmodium falciparum malaria patients using mathematical modeling","volume":"62","author":"Dini","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0130","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.mib.2013.07.005","article-title":"Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins","volume":"16","author":"Klonis","year":"2013","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.pt.2019.05.002_bb0135","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1021\/jo050385+","article-title":"Dispiro-1,2,4-trioxane analogues of a prototype dispiro-1,2,4-trioxolane: mechanistic comparators for artemisinin in the context of reaction pathways with iron(II)","volume":"70","author":"Tang","year":"2005","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.pt.2019.05.002_bb0140","first-page":"293","article-title":"Bioavailable iron and heme metabolism in Plasmodium falciparum","volume":"295","author":"Scholl","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.pt.2019.05.002_bb0145","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.00574-16","article-title":"Comparison of the exposure time-dependence of the activities of synthetic ozonide antimalarials and dihydroartemisinin against K13 wild-type and mutant Plasmodium falciparum strains","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01566-17","article-title":"Parasite-mediated degradation of synthetic ozonide antimalarials impacts in vitro antimalarial activity","volume":"62","author":"Giannangelo","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0155","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1002\/anie.200604697","article-title":"Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs","volume":"46","author":"Stocks","year":"2007","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.pt.2019.05.002_bb0160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/jac\/dkn315","article-title":"In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum","volume":"62","author":"Hofer","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jac\/dkl209","article-title":"In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277\/RBx-11160 in cultures of Plasmodium falciparum","volume":"58","author":"Maerki","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0170","article-title":"Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2019.05.002_bb0175","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/cmdc.201200383","article-title":"Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model-a unifying proposal for drug action","volume":"7","author":"Haynes","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pt.2019.05.002_bb0180","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nature14412","article-title":"A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria","volume":"520","author":"Mbengue","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pt.2019.05.002_bb0185","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/acsinfecdis.5b00090","article-title":"Monoclonal antibodies that recognize the alkylation signature of antimalarial ozonides OZ277 (arterolane) and OZ439 (artefenomel)","volume":"2","author":"Jourdan","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0190","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1002\/anie.201512062","article-title":"A click chemistry-based proteomic approach reveals that 1,2,4-trioxolane and artemisinin antimalarials share a common protein alkylation profile","volume":"55","author":"Ismail","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.pt.2019.05.002_bb0195","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1128\/AAC.01224-16","article-title":"Metabolomic profiling of the malaria box reveals antimalarial target pathways","volume":"60","author":"Allman","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0200","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.01033-07","article-title":"Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials","volume":"52","author":"Creek","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0205","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1016\/j.bmcl.2009.07.013","article-title":"Spiroadamantyl 1,2,4-trioxolane, 1,2,4-trioxane, and 1,2,4-trioxepane pairs: relationship between peroxide bond iron(II) reactivity, heme alkylation efficiency, and antimalarial activity","volume":"19","author":"Wang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pt.2019.05.002_bb0210","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/(SICI)1521-3773(19990903)38:17<2580::AID-ANIE2580>3.0.CO;2-J","article-title":"Interaction of qinghaosu (artemisinin) with cysteine sulfhydryl mediated by traces of non-heme iron","volume":"38","author":"Wu","year":"1999","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.pt.2019.05.002_bb0215","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1039\/b006906j","article-title":"A possible antimalarial action mode of qinghaosu (artemisinin) series compounds. Alkylation of reduced glutathione by C-centered primary radicals produced from antimalarial compound qinghaosu and 12-(2,4-dimethoxyphenyl)-12-deoxoqinghaosu","volume":"22","author":"Wang","year":"2000","journal-title":"Chem. Commun."},{"key":"10.1016\/j.pt.2019.05.002_bb0220","doi-asserted-by":"crossref","first-page":"8207","DOI":"10.1021\/jm2012003","article-title":"Investigating the antimalarial action of 1,2,4-trioxolanes with fluorescent chemical probes","volume":"54","author":"Hartwig","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2019.05.002_bb0225","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/infdis\/jiv372","article-title":"Metabolic dysregulation induced in Plasmodium falciparum by dihydroartemisinin and other front line antimalarial drugs","volume":"213","author":"Cobbold","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0230","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1128\/AAC.01226-16","article-title":"Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action","volume":"60","author":"Creek","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0235","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1128\/AAC.02647-14","article-title":"Fatty acid synthesis and pyruvate metabolism pathways remain active in dihydroartemisinin-induced dormant ring stages of Plasmodium falciparum","volume":"58","author":"Chen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0240","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1073\/pnas.1217452110","article-title":"Altered temporal response of malaria parasites determines differential sensitivity to artemisinin","volume":"110","author":"Klonis","year":"2013","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2019.05.002_bb0245","first-page":"406","article-title":"Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins","volume":"129","author":"Xie","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.pt.2019.05.002_bb0250","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/jps.20958","article-title":"Iron-mediated degradation kinetics of substituted dispiro-1,2,4-trioxolane antimalarials","volume":"96","author":"Creek","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.pt.2019.05.002_bb0255","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00172-17","article-title":"Plasmodium falciparum K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro","volume":"8","author":"Straimer","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.pt.2019.05.002_bb0260","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1475-2875-11-355","article-title":"In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam","volume":"11","author":"Hien","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0265","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1093\/jac\/dkw174","article-title":"Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers","volume":"71","author":"McCarthy","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0270","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiw128","article-title":"Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia","volume":"214","author":"Marquart","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021914","article-title":"A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs","volume":"6","author":"McCarthy","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2019.05.002_bb0280","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1128\/AAC.02883-15","article-title":"Linking murine and human Plasmodium falciparum challenge models in a translational path for antimalarial drug development","volume":"60","author":"McCarthy","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0285","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/dmd.30.9.1005","article-title":"Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases","volume":"30","author":"Ilett","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pt.2019.05.002_bb0290","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1128\/AAC.00183-15","article-title":"Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: Implications for clinical treatment and pharmacokinetic and in vitro assays","volume":"59","author":"Parapini","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0295","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2008.01.087","article-title":"Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277","volume":"18","author":"Zhou","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pt.2019.05.002_bb0300","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00618-17","article-title":"A dynamic stress model explains the delayed drug effect in artemisinin treatment of Plasmodium falciparum","volume":"61","author":"Cao","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0305","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1086\/650301","article-title":"In vivo parasitological measures of artemisinin susceptibility","volume":"201","author":"Stepniewska","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0310","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0315","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/infdis\/jix156","article-title":"Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium falciparum","volume":"215","author":"Siddiqui","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0320","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1260403","article-title":"Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance","volume":"347","author":"Mok","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pt.2019.05.002_bb0325","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2017-11-814665","article-title":"Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance","volume":"131","author":"Bhattacharjee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pt.2019.05.002_bb0330","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature16936","article-title":"Structure- and function-based design of Plasmodium-selective proteasome inhibitors","volume":"530","author":"Li","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pt.2019.05.002_bb0335","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13059-017-1204-4","article-title":"Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance","volume":"18","author":"Cerqueira","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.pt.2019.05.002_bb0340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.parint.2010.09.009","article-title":"Implication of intracellular glutathione and its related enzymes on resistance of malaria parasites to the antimalarial drug arteether","volume":"60","author":"Chandra","year":"2011","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.pt.2019.05.002_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006930","article-title":"Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites","volume":"14","author":"Rocamora","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2019.05.002_bb0350","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1007\/s00436-017-5647-z","article-title":"Cellular mechanisms of action and resistance of Plasmodium falciparum to artemisinin","volume":"116","author":"Phompradit","year":"2017","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.pt.2019.05.002_bb0355","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12936-016-1206-9","article-title":"Plasmodium falciparum: multifaceted resistance to artemisinins","volume":"15","author":"Paloque","year":"2016","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0360","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1021\/acs.biochem.7b00416","article-title":"Heterologous expression, purification, and functional analysis of Plasmodium falciparum phosphatidylinositol 3\u2032-kinase","volume":"56","author":"Hassett","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.pt.2019.05.002_bb0365","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12936-018-2532-x","article-title":"A single nucleotide polymorphism in the Plasmodium falciparum atg18 gene associates with artemisinin resistance and confers enhanced parasite survival under nutrient deprivation","volume":"17","author":"Breglio","year":"2018","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0370","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1475-2875-12-118","article-title":"Artemisinin resistance in rodent malaria \u2013 mutation in the AP2 adaptor \u03bc-chain suggests involvement of endocytosis and membrane protein trafficking","volume":"12","author":"Henriques","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0375","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1128\/AAC.00857-16","article-title":"Endoperoxide drug cross-resistance patterns for Plasmodium falciparum exhibiting an artemisinin delayed-clearance phenotype","volume":"60","author":"Siriwardana","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0380","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12936-017-1696-0","article-title":"In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate","volume":"16","author":"Baumg\u00e4rtner","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0385","doi-asserted-by":"crossref","first-page":"12513","DOI":"10.1073\/pnas.1813386115","article-title":"Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model","volume":"115","author":"S\u00e1","year":"2018","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2019.05.002_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019283","article-title":"Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: A randomized clinical trial","volume":"6","author":"Bethell","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2019.05.002_bb0395","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3201\/eid2304.161872","article-title":"Treatment failure of dihydroartemisinin\/piperaquine for Plasmodium falciparum malaria, Vietnam","volume":"23","author":"Phuc","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0400","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12936-017-1680-8","article-title":"Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin\u2013piperaquine in the south of Vietnam","volume":"16","author":"Thanh","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0405","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4269\/ajtmh.2010.10-0158","article-title":"Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria","volume":"83","author":"Creek","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2019.05.002_bb0410","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1021\/acs.molpharmaceut.8b00173","article-title":"The curious case of the OZ439 mesylate salt: An amphiphilic antimalarial drug with diverse solution and solid state structures","volume":"15","author":"Clulow","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pt.2019.05.002_bb0415","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1021\/acs.molpharmaceut.8b00541","article-title":"Interactions of artefenomel (OZ439) with milk during digestion: Insights into digestion-driven solubilization and polymorphic transformations","volume":"15","author":"Salim","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pt.2019.05.002_bb0420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2875-6-81","article-title":"In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai\u2013Burmese border","volume":"6","author":"Barends","year":"2007","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0425","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1128\/AAC.00060-08","article-title":"In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum","volume":"52","author":"Henry","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0430","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"Noedl","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2019.05.002_bb0435","series-title":"Status Report on Artemisinin and ACT Resistance","author":"WHO","year":"2017"},{"key":"10.1016\/j.pt.2019.05.002_bb0440","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/infdis\/jiu491","article-title":"Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in southeast Asia","volume":"211","author":"Takala-Harrison","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0445","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1473-3099(15)70032-0","article-title":"Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker","volume":"15","author":"Tun","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0450","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1128\/AAC.01255-15","article-title":"Artemisinin resistance at the China\u2013Myanmar border and association with mutations in the K13-propeller gene","volume":"59","author":"Wang","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0455","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/infdis\/jiv249","article-title":"A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment","volume":"212","author":"Huang","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0460","article-title":"Novel pfkelch13 gene polymorphism associates with artemisinin resistance in eastern India","author":"Das","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0465","series-title":"Artemisinin Resistance and Artemisinin-based Combination Therapy Efficacy: Status Report","author":"WHO","year":"2018"},{"key":"10.1016\/j.pt.2019.05.002_bb0470","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.1260867","article-title":"Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates","volume":"347","author":"Straimer","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pt.2019.05.002_bb0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pt.2019.05.002_bb0480","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1128\/AAC.03055-14","article-title":"Plasmodium falciparum founder populations in western Cambodia have reduced artemisinin sensitivity in vitro","volume":"58","author":"Amaratunga","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0485","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.1211205110","article-title":"Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia","volume":"110","author":"Takala-Harrison","year":"2013","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2019.05.002_bb0490","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ng.3189","article-title":"Genetic architecture of artemisinin-resistant Plasmodium falciparum","volume":"47","author":"Miotto","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.pt.2019.05.002_bb0495","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","article-title":"A worldwide map of Plasmodium falciparum K13-propeller polymorphisms","volume":"374","author":"M\u00e9nard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2019.05.002_bb0500","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/QCO.0000000000000199","article-title":"Understanding artemisinin-resistant malaria: what a difference a year makes","volume":"28","author":"Fairhurst","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0505","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/infdis\/jiu467","article-title":"Absence of putative Plasmodium falciparum artemisinin resistance mutations in sub-Saharan Africa: A molecular epidemiologic study","volume":"211","author":"Taylor","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0510","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMc1612765","article-title":"Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa","volume":"376","author":"Lu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2019.05.002_bb0515","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1128\/AAC.00197-15","article-title":"Artemisinin-resistant Plasmodium falciparum exhibit altered patterns of development in infected erythrocytes","volume":"59","author":"Hott","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0520","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1128\/AAC.01868-12","article-title":"Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia","volume":"57","author":"Witkowski","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2019.05.002_bb0525","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12936-018-2418-y","article-title":"Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model","volume":"17","author":"Scott","year":"2018","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0530","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.1615875114","article-title":"Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort","volume":"114","author":"Ataide","year":"2017","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2019.05.002_bb0535","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/infdis\/jix371","article-title":"Declining transmission and immunity to malaria and emerging artemisinin resistance in Thailand: a longitudinal study","volume":"216","author":"Ata\u00edde","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0540","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/infdis\/jit082","article-title":"Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity","volume":"207","author":"Lopera-Mesa","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2019.05.002_bb0545","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12936-017-1815-y","article-title":"Immunity as a predictor of anti-malarial treatment failure: a systematic review","volume":"16","author":"O\u2019Flaherty","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0550","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12936-018-2278-5","article-title":"Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar","volume":"17","author":"Lohy Das","year":"2018","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2019.05.002_bb0555","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1475-2875-10-181","article-title":"Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria","volume":"10","author":"Jamsen","year":"2011","journal-title":"Malar. J."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492219301035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492219301035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:34:25Z","timestamp":1761464065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492219301035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1471492219301035"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2019.05.002","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}